A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects With Chronic Hepatitis C Infection.

Trial Profile

A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects With Chronic Hepatitis C Infection.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2018

At a glance

  • Drugs Antivirals (Primary) ; Ledipasvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary) ; Sofosbuvir/velpatasvir/voxilaprevir (Primary) ; Tegobuvir (Primary) ; Vedroprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 03 Feb 2018 The study had been Discontinued in Austria.
    • 04 Jan 2018 The study had been completed in Spain.
    • 28 Dec 2017 This trial has been completed in Germany.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top